官方新闻稿指出，Breyanzi在边缘区淋巴瘤（MZL）队列中达到了总缓解率（ORR）的主要终点及完全缓解率（CRR）的关键次要终点，结果展现出统计学显著性。同时，Breyanzi表现出持久的疗效和一致的安全性特征，且未观察到新的安全性信号。

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

The Maharashtra CET Cell has announced that the Maha CET 2025 for BCA/BBA/BMS/BBM/MBA(integrated)/MCA(integrated) course is ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...

There are few details available yet on the BMS partnership, other than the two companies will work on improving the efficiency and precision of clinical trials, initially in cardiovascular disease ...

The drug generated $4.4 billion in the first 9 months of 2024, but BMS expects an "additional step down” to $2 billion to $2.5 billion in 2025. In addition, Pomalyst and Sprycel are expected to ...